BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/8/2024 7:49:57 AM | Browse: 174 | Download: 824
 |
Received |
|
2024-01-24 07:29 |
|
Peer-Review Started |
|
2024-01-24 07:29 |
|
First Decision by Editorial Office Director |
|
2024-02-27 04:08 |
|
Return for Revision |
|
2024-02-27 04:08 |
|
Revised |
|
2024-03-05 08:54 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-04-23 23:59 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-04-30 09:48 |
|
Articles in Press |
|
2024-04-30 09:48 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-06-24 03:23 |
|
Publish the Manuscript Online |
|
2024-07-08 07:49 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus: A systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiao-Lan Ma, Dan Ge and Xue-Jian Hu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xue-Jian Hu, MM, Doctor, Doctor, Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Lanzhou University, No. 82 Linxia Road, Lanzhou 730000, Gansu Province, China. xuejian2023@sina.com |
| Key Words |
Type-1 diabetes mellitus; Teplizumab; Anti-CD3 monoclonal antibody; Insulin; Glycated haemoglobin A1c; C-peptide |
| Core Tip |
Type 1 diabetes mellitus (T1DM) may benefit from teplizumab. However, there is limited data on its long-term effects on clinical T1DM development, safety, and efficacy. Given its perceived use, this research evaluated the effectiveness and safety of teplizumab for T1DM patients through a systematic review and meta-analysis of 8 randomized controlled trials, including 1908 patients from various age groups. It was found that teplizumab treatment results in reduced insulin use, improved C-peptide response, significant glycated haemoglobin A1c changes in T1DM patients with minimal side effects and improved glycaemic management. |
| Publish Date |
2024-07-08 07:49 |
| Citation |
Ma XL, Ge D, Hu XJ. Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus: A systematic review and meta-analysis. World J Diabetes 2024; 15(7): 1615-1626 |
| URL |
https://www.wjgnet.com/1948-9358/full/v15/i7/1615.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v15.i7.1615 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
